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Abstract 
Cannabidiol (CBD) is an alkaloid that can be found in the Cannabis species, currently used in United States of America 
under the name of Epidiolex®, which was approved by Food and Drug Administration (FDA) for seizures treatment. The 
purpose of this study was to investigate the structural characteristics of the raw materials and to compare 2 film formulations 
with different analytical methods. In order to differentiate the structural properties, the following methods were used: X-ray 
powder diffraction (XRPD) and Fourier transform-infrared (FTIR) spectroscopy. The thermal properties of the raw materials 
and films was also obtained using differential scanning calorimetry (DSC) and thermogravimetry analysis (TGA). As in the 
case of structural properties for the thermal decomposition, two films formulations that presented the highest differences 
were selected. Thermal analysis, FTIR and XRPD were utilized to present the characteristics of the raw materials and the 
selected orodispersible films. 
 
Rezumat 
Canabidiolul (CBD) este unul din alcaloizii ce se regăsește în speciile de Cannabis. Ca produs medicamentos este prezent în 
Statele Unite ale Americii sub denumirea comercială de Epidiolex® (medicament aprobat de Food and Drug Administration - 
FDA) pentru tratamentul epilepsiei. Scopul acestui studiu constă în prezentarea caracteristicilor structurale ale excipienților, 
substanței active, respectiv compararea a două formulări de filme orodispersabile prin metode analitice diferite. Pentru a pune 
în evidență proprietățile structurale ale formularilor s-au folosit următoarele metode: difracția de raze X și spectrometria în 
infraroșu cu transformată Fourier. Proprietățile termice ale excipienților, substanței active precum și cele ale filmelor au fost 
analizate utilizând calorimetria cu scanare diferențială și analiza termogravimetrică. La fel ca în cazul analizei proprietăților 
structurale, și în cazul analizei termice au fost selectate două formulări de filme ce au prezentat proprietăți distincte. FTIR și 
XRPD au fost utilizate pentru a evidenția proprietățile structurale, cele termice fiind evaluate utilizând DSC și ATG. 
 





diol, is an phytocannabinoid that can be found in 
the Cannabis sativa species [24]. An oily solution 
containing CBD called Epidiolex
®
 was approved by 
FDA in 2018 and represents until now the only 
approved pharmaceutical formulation worldwide 
containing only CBD [22]. Epidiolex
®
 has been 
approved in the treatment of Lennox-Gastaut and 
Dravet syndromes [5, 7, 11]. 
Developing an orodispersible formulation represents 
a challenge due to the maximum disintegration time 
that has to be less than a few seconds. Besides the 
improved bioavailability, an orodispersible formulation 
in this case orodispersible films (ODFs) may confer 
other advantages such as: noninvasively route of 
administration, ease of administration for patients who 
present physiological impairments such as dysphagia 
and a fast release of the API [9, 27, 28]. Likewise, 
good pharmacotechnical and mechanical properties 
need to be taken into consideration [1, 12]. 
Usually, TG and DSC are used for the characterization 
of powder and binary mixtures [15]. This method 
offers an evaluation of the thermal characteristics, 
dehydration and could be a tool for describing 
possible interactions between the API and excipients 
[6, 23]. It can be used also in the evaluation of the 
absorption or desorption of water [15]. In our study 
thermal analysis was conducted to acquire the thermal 
properties of the powders and two CBD-ODFs. The 
thermal and structural characterization of ODFs or 
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thin films has been used recently to establish the 
most stable formulation [17]. 
The present study aimed to evaluate the structural 
characteristics of the raw materials and two film 
formulations that with the selected analytical methods 
presented different properties. To obtain a structural 
characterization of the films FTIR and XRPD 
evaluation were made while for thermal analysis, 
DSC and TG analysis was conducted. Two oro-
dispersible film formulations were selected to high-
light the structural and thermal dissimilarities. 
 
Materials and Methods 
Materials 
The materials used were: CBD 99.5% purity, Trigal 
Pharma (Austria), Hypromellose (Vivapharm HPMCE3) 
which was a kind gift from JRS Pharma (Germany). 
The other substances used were: citric acid (CA) 
Fooding (France), sorbitol (SRB) Falken Trade 
GmbH, (Germany), propylene glycol (PG) SKC 
Korea, (South Korea) and peach flavour Carmi Flavor 
and Fragrance (United States of America). 
Methods 
Preparation of CBD-ODFs 
The films were prepared by solvent casting method 
and had a varied composition. The excipients whose 
concentration was diversified were Vivapharm HPMCE3, 
utilized as a film-forming agent and PG, used as a 
plasticizer. Water and varied amount of alcohol 
were used as solvent system. Firstly, the film-
forming agent was dissolved into water under 
continuous stirring at room temperature. After a clear 
solution was obtained the following components were 
added: CA, PG, SRB and, PFL. Separately, CBD 
was dissolved in 96% alcohol. The obtained 
alcoholic solution was added over the aqueous 
solution under continuous stirring drop by drop 
(Table I). The mixture was cast into a plastic ring 
having definite thickness and diameters and dried at 
room temperature for 24 hours (Figure 1). The films 
were tested within one week after the production 
process (Table II). The samples were stored in the 
refrigerator at a temperature of 5 ± 2°C as prevent 
deterioration and API decomposing. 
Table I 
Composition of CBD-ODF 
 
Concentration of the ingredients (%) 
F1 F2 F3 
CBD 1.25 1.25 1.25 
HPMCE3 5 5 9 
PG 0.5 2.5 2.5 
CA 1 1 1 
SRB 1 1 1 
PFL 1 1 1 
Alcohol 45.25 44.25 43.25 
Water 45 44 42 
CBD = Cannabidiol, HPMCE3 = Hypromellose Vivapharm,  
PG = propylene glycol, CA = citric acid, SRB = sorbitol, 




The process of solvent casting method applied to obtain the CBD-ODFs 
 
Table II 
The structural and thermal behaviour described by different analytical methods 
Substance/mixture Code Analytical methods 
Cannabidiol CBD FTIR, XRPD, DSC, TG 
Vivapharm HPMCE3 HPMCE3 FTIR, XRPD, DSC, TG 
Citric acid CA FTIR, XRPD, DSC, TG 
Sorbitol SRB FTIR, XRPD, DSC, TG 
Peach flavour PFL FTIR, XRPD, DSC, TG 
Orodispersible films F1, F2 DSC, TG 
 F1, F3 FTIR, XRPD 
 
FARMACIA, 2021, Vol. 69, 3 
 428 
Structural analysis 
Fourier transform-infrared (FTIR) spectroscopy 
The FTIR spectra of the films, CBD and for the 
excipients were achieved by a FTIR (Avatar 330 
FT-IR Thermo Scientific, USA) spectrophotometer. 
128 scans in the spectral range of 400 to 4000 cm
-1
 
for raw material and from 600 to 4000 cm
-1
 for the 
films, at a spectral resolution of 4 cm
-1 
were obtained 
using an EzOMNIC 10.1 software. Three spectra 
for both raw materials and films were averaged. To 
obtain the maximum peak linked to different 
functional groups or representing a characteristic peak 
for the substance/film; SpectraGryph Software 1.2 
was used. 
X-ray powder diffraction (XRPD) analysis 
Crystal/amorphous structure of the excipients, CBD 
and for F1 and F3 was verified to see if the 
components are maintaining their characteristics 
signal after mixing them and obtaining the CBD-
ODFs. For this determination, a Bruker D8 Advance 
diffractometer was used (Bruker AXS GmbH, 
Karlsruhe, Germany). 
The experiments were performed in symmetrical 
reflection mode with Cu Kα1 radiation (λ = 1.5406 Å), 
using Göbel Mirror bent gradient multilayer optics. 
The scattered intensities were measured with a 
Våntec-1 line detector. The angular range was from 
3° to 30° in steps of 0.007°. Other measurement 
conditions were as follows: target, Cu; filter, Ni; 
voltage, 40 kV; current, 40 mA; measuring time, 0.1 s 
per step. F1 and F3 were analysed using this method. 
Thermal Analysis 
Thermogravimetric (TGA) and DSC analysis 
The TGA and DSC analysis was conducted on powders 
and films. The thermal analysis of the samples was 
carried out with a Mettler-Toledo TGA/DSC1 instrument 
(Mettler-Toledo GmbH, Switzerland). Quantities 
between 9.51 mg and 10.80 mg of mixtures and 
films were placed in a closed aluminium crucible 
with a volume of 40 µL. The temperature range was 
between 25 - 500°C, the heating rate was 10°C/min. 
Nitrogen atmosphere was used (Cell gas: 50 mL/min, 
method gas: 70 mL/min). Evaluation of the curves 
was acquired with STAR
e
 Software. For the TGA 
and DSC analysis the F1 and F2 CBD-ODFs were 
examined beside the raw materials. 
 
Results and Discussion 
Structural analysis 
Fourier transform-infrared (FTIR) spectroscopy 
FTIR results of the raw materials and the CBD-
ODFs can be found in Figures 2 and 3 and Table III. 
The substances analysed were: CBD-a cannabinoid, 
Hypromellose-Vivapharm HPMCE3, CA-used as a 
taste-masking agent [20], saliva stimulating agent [4] 
while other studies showed that it could be used as a 
plasticizer [18], SRB-a non-cariogenic sweetener [26], 
PFL-taste masking agent and flavouring agent. The 








FTIR spectra of CBD-ODFs 




Wavenumbers of characteristic peaks of the API and the raw materials 
Raw material Wavenumbers of characteristic peaks (cm-1) 
CBD 3423.3; 1620; 1638; 1590; 578 
SRB 2926.2; 1638, 1254.1; 1095; 1048.6; 1001; 1016, 669; 644 
HPMCE3 3485; 1734; 1635; 1052; 943,75; 668; 570; 472. 
CA 3431; 3496; 1749; 1700; 1173; 1142; 940; 880; 778; 688; 640; 597; 548; 498 
PFL 3485; 3238; 1645; 1737; 1780; 1154; 1080; 1023; 926; 762; 708; 669; 578; 525 
CBD = Cannabidiol, HPMCE3 = Hypromellose Vivapharm, CA = citric acid, SRB = sorbitol, PFA = peach flavour Carmi Flavour and Fragrance  
 
The presence of the CBD in the films (Figure 3) 
can be noticed taking into consideration the bands 
of the C=C and =C-H aliphatic groups, which were 
characteristic only to the API. In the formulated 
films the C=C bond appeared while the F3 was the 
only film compositions where the =C-H did not 
possess a prominent absorption band. All the FTIR 
spectra of the films present the following characteristic 
bands: 2915 - 2921 cm
-1
 which represented a tensile 
vibration given by the -OH. The peak between 1723 
cm
-1
 and 1730 cm
-1
 is characteristic to the C=O 
stretch which is specific for carboxylic acids. The 
C=O stretch can be representative for the CA which 
has three carboxylic groups. The peak at 1443 cm
-1 
cannot be considered as a particular peak because, 
it is characteristic to methylene or methoxy groups 
(asymmetric aliphatic C-H deformation), so this 
peak could belong to the PG, CBD and HPMCE3. 
The absorption band at 1373 cm
-1
 belongs to a 
symmetric aliphatic C-H bending of methyl groups 
that can be noticed. It can belong to: CBD, CA, 
SRB, PG and HPMCE3. The strong absorption band at 
1200 cm
-1
 can be assigned to the asymmetric 
stretching of the major function group (C-O-C) can 
be attributed to PFL and HPMCE3. 
FTIR spectra showed that even when the final mixture 
of ODF was obtained the CBD still could be identified 
and the excipients used did not significantly alter the 
characteristic bands of the API. Also, characteristic 
bands were identified for the excipients used in the 
films.  
X-ray powder diffraction (XRPD) analysis 
XRPD studies for the CBD, excipients and, two 
film formulations are shown in Figure 4. 
Between the solid components, two presented an 
amorphous state, PFL and HPMCE3 while the active 
ingredient, CA and SRB showed a crystalline state 
each one of them offering distinctive peaks at different 
2θ values. The 2θ angle values characteristic for CBD 
are: 9.55, 10.16, 13.36 and 15.49, the highest intensity 
occurring in the case of the 9.55. In addition, the 
diffractograms of the CA presented the following 
peaks 17.93 (highest intensity), 19.48, 23.47 and 25.98 
while for the other substance that showed also a 
crystalline structure, SRB, the characteristic peaks 
were: 18.32 (highest intensity), 20.23 and 25.66. Even 
though HPMCE3 and PFL showed an amorphous 
structure, HPMCE3 offered two signals at 6 and 20 
Bragg’s angles while PFL presented an increased 




XRPD patterns of CBD, excipients; F1 and F3 ODFs 
 
The same findings were obtained in the case of CA 
by Ortega-Toro [10]. The CA presented the same 
characteristic peaks as the one presented in this paper 
the only difference consisting in the double dentate 
peak at 23.47 while our results show only one peak 
at that 2 θ value. Different peak shapes could be 
attributed to the following factors: crystallite size, 
strain, and paracrystallinity [25]. In the same study 
conducted by Ortega-Toro, a semicrystalline structure 
could be noticed even after obtaining the films, 
while in this paper an amorphous mixture resulted 
[10]. The amount of HPMCE3 can be noticed. As a 
result, in the F3 the characteristic signal of HPMCE3 
could be easily observed. As shown in the literature a 
crystalline structure of the film might be a dis-
advantage since the stretchability could be affected 
because of the limited displacement of macromolecule 
[4]. The amorphous state which can be observed in 
the case of the CBD-ODFs resulted might be considered 
an advantage because CBD has a low solubility and 
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the HPMCE3 can exert solubility enhancing properties 
as shown in the cases of other poorly water-soluble 
drugs such as nimodipine [13], carbamazepine [8] and 
nisoldipine [3]. 
In the case of SRB, the literature is mixed some of 
the results showing that an increased concentration of 
SRB might conduct to a diminished crystallinity as 
described in Somashekarappa et al. [19], while most 
of the studies showed that an increased concentration 
of SRB might conduct to semicristalinity in thin 
films as stated by Sun et al. [21]. 
In the case of F1, PG and HPMCE3 concentration 
were the lowest (0.5% - PG and 5% HPMCE3) while 
in the F3 formulation the highest concentrations of 
PG and HPMCE3 were used (2.5% PG and 9% 
HPMCE3). Between the two films no major 
differences were observed, none of them presenting 
crystalline structure, both being amorphous due to the 
presence of HPMCE3 which is similar to the results 
obtained by Rotta et al. [14] and Sakata et al. [16]. 
Thermal analysis 
Thermogravimetric analysis 
In the present case, TGA was utilized as an evaluation 
tool (Figure 5). Besides the thermal analysis of the 
powders, the thermal stability of the CBD-ODFs F1 
and F2 formulations will be discussed.  
Thermal decomposition of the CBD, CA and SRB 
took place in one step, in the case of the film-forming 
agent in 3 steps while for the films F1 and F2 and 




Differential scanning calorimetry (DSC) and thermogravimetric (TG) curves of CBD and excipients 
 
In both cases the thermal decomposition of the 
films took place in two steps as in the case of the 
other amorphous substances used to obtain the 
CBD-ODFs, the first step usually corresponding to 
water loss. The other substances that might be 
involved in this first step thermal mass loss could 
be alcohol (due to its volatility) and the peach 
flavour (due to its complex composition). Even 
though the values of the mass loss are very close in 
the case of F2 a higher loss can be observed 
(89.161%) while for F1 (80.565%) - between 25 
and 500°C. Considering the weight loss percentage, 
F1 might be considered the most stable film. As can 
be seen in Figure 6, in both cases the main 
decomposition starts at temperatures over 160°C as 
a result of the accentuated weight loss. Even though 
the thermal decomposition of the HPMCE3 itself 
starts at lower temperatures 120°C, the other film 
excipients, the film structure and the interactions 
between the polymer-plasticizer (HPMCE3-PG) and 
polymer-CA (HPMCE3-CA) might be an explanation 
for the higher temperature at which the decomposition 
starts. The second and third endothermic peak correspond 
to film-forming agent decomposition as in the case 
of the fourth peak which was exothermic. 
DSC Analysis 
The DSC curve (Figure 5) of CBD presented two 
endothermic processes indicating the melting point at 
71.32°C. The Tonset was 67.51°C, Tendset was 75.34°C 
and H = 60.6 J/g. The decomposition is indicated 
by the second endothermic curve which is starting at 
a higher temperature of Tonset of 302.99°C and a 
Tendset of 367.87°C with Tpeak 338.76°C. 
The DSC profile for HPMCE3 only one endothermic 
event could be identified with the peak at 71.40°C, 
Tonset at 40.61°C and Tendset at 101.56°C indicating 
the melting point while the decomposition starts at 
higher temperatures than 120°C. 
In the case of CA, two large endothermic events were 
recorded between 154.46 and 162.57°C with a Tpeak = 
156.69°C representing the melting point while the 
second one revealed the decomposition which started 
between 182.04°C and ended at 242.24°C with a 
Tpeak = 220.47°C. The same behaviour was registered 
in the case of SRB were also two endothermic 
points were recorded. The first endothermic peak 
FARMACIA, 2021, Vol. 69, 3 
 431 
started at 96.50°C and ended at 107.20°C with a 
Tpeak = 100.81°C while the second one started at 
310.70°C and ended at 391.19°C with a Tpeak = 
374.65°C. The first peak belonged to the melting 
point while the second matched the decomposition 




Differential scanning calorimetry (DSC) and thermogravimetric (TG) curves of F1, F2 CBD-ODFs 
 
For the flavouring agent, two endothermic peaks were 
recorded with the first corresponding to melting 
point followed by the second one which belonged 
to the decomposition. The melting point started at 
54.82°C and ended at 150.32°C with a Tpeak of 96.21°C 
while the decomposition started at 216.80°C and 
ended at 233.76°C with a Tpeak of 223.04°C. 
As it can be observed in Figure 6, four thermal events 
occurred in the case of the F1 and F2 CBD-ODFs 
studied from which the first three were endothermic 
while the fourth one was exothermic (Table IV). 
Table IV 
Thermoanalytical DSC data of F1 and F2 CBD-ODFs 
Sample Peak nr. Tonset (°C) Tendset (°C) Tpeak(°C) ΔH (J/g) 
F1 1 84.04 136.70 89.78 -55.60 
2 195.49 234.80 205.98 -58.51 
3 264.80 315.12 293.15 -16.74 
4 320.47 425.31 391.98 109.89 
F2 1 41.87 128.30 88.69 -68.59 
2 173.51 231.89 207.84 -55.32 
3 266.57 320.45 293.55 -11.93 
4 358.78 422.74 385.74 68.41 
 
Taking into consideration the Tonset, it can be 
concluded that F2 is a more thermal stable film due 
to the higher value of Tonset. It has to be mentioned 
that small differences between the films regarding 
Tonset were recorded in the case of some peaks, the 
biggest difference between the Tonset of the films 
being registered in the case of the exothermic peak 
(over 5°C), while the smallest occurred in the case of 
the third endothermic peak (less than 1°C). However, 
the films had the same components so the PG 
concentration might be responsible for the peaks 
shifting, because in this case, the concentration of 
HPMCE3 was the same. If the thermal events which 
occurred in the films are compared it can be stated 
that for the exothermic peak, HPMCE3 and peach 
flavour might be responsible, since the crystalline 
substances - CBD, SRB and CA did not present any 
exothermic events only endothermic ones. The first 
peak corresponds to water, alcohol and volatile 
compounds (contained by the PFL) loss, while the 
second, third and fourth correspond to the 
decomposition. Also, the interactions between the 
PG and HPMCE3 might be responsible for the peak 
shifting and the appearance of the highlighted 
exothermic peak which could not be easily observed 
in the case of the amorphous substances. The obtained 
results are confirmed in terms of enthalpy results. 
 
Conclusions 
Thin films with different compositions of plasticizer 
and film-forming agents were successfully obtained. 
The presence of the HPMCE3 conducted to an 
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amorphous structure which could be observed with 
XRPD and might be an advantage due to the solubility 
enhancing properties of the polymer. Structural 
characterization using FTIR, XRPD and thermal 
analysis using DSC and TGA proved to be fast 
screening methods. Although, the CBD-ODFs possess 
a complex composition, the curve profiles of the 
thermograms are relatively simple which may imply 
either an optimal interaction between the components 
either an overlapping of the thermal event of the 
components. 
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